Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

HLA-G 14bp ins/del Polymorphism, Plasma Level of Soluble HLA-G and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients

Maria Bucova
* ,
Kristina Kluckova
* ,
Jan Kozak
,
Boris Rychly
,
Marian Svajdler
ORCID logo ,
Viktor Matejcik
,
Juraj Steno
,
Eszter Zsemlye
,
Vladimíra Ďurmanová
Version 1 : Received: 3 December 2021 / Approved: 7 December 2021 / Online: 7 December 2021 (12:55:23 CET)

How to cite: Bucova, M.; Kluckova, K.; Kozak, J.; Rychly, B.; Svajdler, M.; Matejcik, V.; Steno, J.; Zsemlye, E.; Ďurmanová, V. HLA-G 14bp ins/del Polymorphism, Plasma Level of Soluble HLA-G and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Preprints 2021, 2021120104. https://doi.org/10.20944/preprints202112.0104.v1 Bucova, M.; Kluckova, K.; Kozak, J.; Rychly, B.; Svajdler, M.; Matejcik, V.; Steno, J.; Zsemlye, E.; Ďurmanová, V. HLA-G 14bp ins/del Polymorphism, Plasma Level of Soluble HLA-G and Association with IL-6/IL-10 Ratio and Survival of Glioma Patients. Preprints 2021, 2021120104. https://doi.org/10.20944/preprints202112.0104.v1

Abstract

HLA-G is an immune checkpoint molecule with immunosuppressive and anti-inflammatory activities, and its expression and level of its soluble form (sHLA-G) may play an important role in tumor prognosis. The HLA-G 14 bp ins/del polymorphism and the plasma level of soluble HLA-G (sHLA-G) were investigated by a polymerase chain reaction and ELISA, respectively, in 59 glioma patients. A significantly higher proportion of glioma patients had the 14 nt insert in both homozygous and heterozygous states compared to the control group. Glioma patients had also higher plasma levels of sHLA-G. Patients with methylated MGMT promoter had lower levels of sHLA-G than those with unmethylated MGMT promoter. Level of sHLA-G negatively correlated with the overall survival of patients. Glioblastoma patients who survived more than one year after diagnosis had lower levels of sHLA-G than those surviving less than one year. Patients with sHLA-G levels below the cut off value 40 U/mL survived significantly longer than patients with sHLA-G above 40 U/mL. The levels of sHLA-G also negatively correlated with the level of IL-6 (P=0.0004) and positively with IL-10/IL-6 (P=0.046). Conclusion: The presence of 14 nt insert in both homozygous and heterozygous states of the HLA-G 14 bp ins/del polymorphism is more frequent in glioma patients and the elevated plasma levels of sHLA-G are negatively associated with their survival.

Keywords

glioma; HLA-G; IL-6; polymorphism; prognosis; survival

Subject

Biology and Life Sciences, Immunology and Microbiology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.